MAZE THERAPEUTICS, INC. Research and Development Expense
MAZE THERAPEUTICS, INC. (MAZE) reported Research and Development Expense of $34.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $34.94M, a 24.31% increase year-over-year.
- MAZE THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $34.15M, a 23.81% increase year-over-year.
- MAZE THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $27.57M, a 24.10% increase year-over-year.
- MAZE THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $25.19M, a 26.86% increase year-over-year.
- MAZE THERAPEUTICS, INC. research and development expense for fiscal 2025 was $108.45M, a 29.88% increase from fiscal 2024.
- MAZE THERAPEUTICS, INC. research and development expense for fiscal 2024 was $83.50M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.94M 10-Q · filed 2026-08-11 | $69.09M 10-Q · filed 2026-08-11 | $96.66M derived: sum of 3 quarters · filed 2026-08-11 | $121.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $34.15M 10-Q · filed 2026-05-12 | $61.72M derived: sum of 2 quarters · filed 2026-05-12 | $86.91M derived: sum of 3 quarters · filed 2026-05-12 | $115.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $27.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $52.76M derived: sum of 2 quarters · filed 2026-03-25 | $80.87M derived: sum of 3 quarters · filed 2026-08-11 | $108.45M 10-K · filed 2026-03-25 |
| 2025-09-30 | $25.19M 10-Q · filed 2025-11-06 | $53.30M derived: sum of 2 quarters · filed 2026-08-11 | $80.88M 10-Q · filed 2025-11-06 | $103.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $28.11M 10-Q · filed 2026-08-11 | $55.69M 10-Q · filed 2026-08-11 | $77.90M derived: sum of 3 quarters · filed 2026-08-11 | $97.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $27.58M 10-Q · filed 2026-05-12 | $49.80M derived: sum of 2 quarters · filed 2026-05-12 | $69.65M derived: sum of 3 quarters · filed 2026-05-12 | $89.20M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $22.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $42.07M derived: sum of 2 quarters · filed 2026-03-25 | $61.62M derived: sum of 3 quarters · filed 2026-03-25 | $83.50M 10-K · filed 2026-03-25 |
| 2024-09-30 | $19.86M 10-Q · filed 2025-11-06 | $39.40M derived: sum of 2 quarters · filed 2025-11-06 | $61.28M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $19.55M 10-Q · filed 2025-08-12 | $41.42M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $21.88M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |